Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
Clinical trial NCT03078751 · COMPLETED
Trial details
- NCT number
- NCT03078751
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-20
- Primary completion
- 2020-03-09
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.